Shire PLC (NASDAQ:SHPG) has been given a $222.00 price objective by equities researchers at Cantor Fitzgerald in a report issued on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 50.23% from the stock’s previous close.

The analysts wrote, “This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP).””

Several other analysts also recently weighed in on the company. HSBC Holdings plc downgraded Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. Royal Bank Of Canada set a $221.00 price objective on Shire PLC and gave the stock a “buy” rating in a research report on Thursday, May 18th. Sanford C. Bernstein downgraded Shire PLC from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $209.22 to $161.09 in a research report on Thursday, May 25th. BidaskClub raised Shire PLC from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Finally, ValuEngine cut Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $222.27.

Shares of Shire PLC (NASDAQ:SHPG) traded up 0.19% during mid-day trading on Tuesday, reaching $148.05. The company’s stock had a trading volume of 819,455 shares. Shire PLC has a 52-week low of $147.28 and a 52-week high of $209.22.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.53 by $0.20. Shire PLC had a return on equity of 3.18% and a net margin of 6.33%. The firm had revenue of $3.75 billion for the quarter. During the same period in the previous year, the firm posted $3.38 earnings per share. The firm’s quarterly revenue was up 54.2% on a year-over-year basis. Equities research analysts anticipate that Shire PLC will post $14.95 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/15/shire-plc-shpg-earns-buy-rating-from-cantor-fitzgerald.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of SHPG. Whittier Trust Co. raised its position in Shire PLC by 19.1% in the first quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 92 shares in the last quarter. Hartford Financial Management Inc. raised its position in Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 32 shares in the last quarter. Thompson Davis & CO. Inc. raised its position in Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 19 shares in the last quarter. YorkBridge Wealth Partners LLC raised its position in Shire PLC by 81.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares in the last quarter. Finally, FTB Advisors Inc. raised its position in Shire PLC by 11.1% in the first quarter. FTB Advisors Inc. now owns 749 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 75 shares in the last quarter. Hedge funds and other institutional investors own 20.22% of the company’s stock.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.